Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/1492
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | KRETZER, Iara F. | - |
dc.contributor.author | MARIA, Durvanei A. | - |
dc.contributor.author | MARANHAO, Raul C. | - |
dc.date.accessioned | 2013-07-30T17:52:34Z | - |
dc.date.available | 2013-07-30T17:52:34Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | CELLULAR ONCOLOGY, v.35, n.6, p.451-460, 2012 | - |
dc.identifier.issn | 2211-3428 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/1492 | - |
dc.description.abstract | Lipid nanoemulsions (LDE) may be used as carriers of paclitaxel (PTX) and etoposide (ETP) to decrease toxicity and increase the therapeutic action of those drugs. The current study investigates the combined chemotherapy with PTX and ETP associated with LDE. Four groups of 10-20 B16F10 melanoma-bearing mice were treated with LDE-PTX and LDE-ETP in combination (LDE-PTX + ETP), commercial PTX and ETP in combination (PTX + ETP), single LDE-PTX, and single LDE-ETP. PTX and ETX doses were 9 mu mol/kg administered in three intraperitoneal injections on three alternate days. In two control groups mice were treated with saline solution or LDE alone. Tumor growth, metastasis presence, cell-cycle distribution, blood cell counts and histological data were analyzed. Toxicity of all treatments was evaluated in mice without tumors. Tumor growth inhibition was similarly strong in all treatment groups. However, there was a greater reduction in the number of animals bearing metastases in the LDE-PTX + ETP group (30 %) in comparison to the PTX + ETP group (82 %, p < 0.05). Reduction of cellular density, blood vessels and increase of collagen fibers in tumor tissues were observed in the LDE-PTX + ETP group but not in the PTX + ETP group, and in both groups reduced melanoma-related anemia and thrombocytosis were observed. Flow cytometric analysis suggested that LDE-PTX + ETP exhibited greater selectivity to neoplastic cells than PTX-ETP, showing arrest (65 %) in the G(2)/M phase of the cell cycle (p < 0.001). Toxicity manifested by weight loss and myelosuppression was markedly milder in the LDE-PTX + ETP than in the PTX + ETP group. LDE-PTX + ETP combined drug-targeting therapy showed markedly superior anti-cancer properties and reduced toxicity compared to PTX + ETP. | - |
dc.description.sponsorship | State of Sao Paulo Foundation for Research Support (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, Brazil [06-58917-3] | - |
dc.description.sponsorship | National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq), Brasilia, Brazil [308238-2006-0] | - |
dc.description.sponsorship | CNPq [134747/2005-4] | - |
dc.language.iso | eng | - |
dc.publisher | SPRINGER | - |
dc.relation.ispartof | Cellular Oncology | - |
dc.rights | restrictedAccess | - |
dc.subject | Nanoparticles | - |
dc.subject | Drug-targeting | - |
dc.subject | Emulsions | - |
dc.subject | Cholesterol | - |
dc.subject | Low-density lipoprotein (LDL) receptors | - |
dc.subject | Cancer treatment | - |
dc.subject.other | low-density-lipoprotein | - |
dc.subject.other | in-vivo | - |
dc.subject.other | microemulsion lde | - |
dc.subject.other | breast-cancer | - |
dc.subject.other | plasma kinetics | - |
dc.subject.other | lipid emulsion | - |
dc.subject.other | cells | - |
dc.subject.other | receptor | - |
dc.subject.other | melanoma | - |
dc.subject.other | leukemia | - |
dc.title | Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion | - |
dc.type | article | - |
dc.rights.holder | Copyright SPRINGER | - |
dc.identifier.doi | 10.1007/s13402-012-0104-6 | - |
dc.identifier.pmid | 23055341 | - |
dc.subject.wos | Oncology | - |
dc.subject.wos | Cell Biology | - |
dc.subject.wos | Pathology | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | KRETZER, Iara F.:Univ Sao Paulo, Med Sch Hosp, Heart Inst INCOR, Lipid Metab Lab, BR-05403900 Sao Paulo, Brazil; Univ Sao Paulo, Fac Pharmaceut Sci, BR-05403900 Sao Paulo, Brazil | - |
hcfmusp.author.external | MARIA, Durvanei A.:Butantan Inst, Biochem & Biophys Labs, Sao Paulo, Brazil | - |
hcfmusp.description.beginpage | 451 | - |
hcfmusp.description.endpage | 460 | - |
hcfmusp.description.issue | 6 | - |
hcfmusp.description.volume | 35 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | 2-s2.0-84879241534 | - |
hcfmusp.origem.id | WOS:000312125000006 | - |
hcfmusp.publisher.city | DORDRECHT | - |
hcfmusp.publisher.country | NETHERLANDS | - |
hcfmusp.relation.reference | Ades A, 2001, GYNECOL ONCOL, V82, P84, DOI 10.1006/gyno.2001.6203 | - |
hcfmusp.relation.reference | Antalis CJ, 2011, CLIN EXP METASTAS, V28, P733, DOI 10.1007/s10585-011-9405-9 | - |
hcfmusp.relation.reference | Azevedo CHM, 2005, GYNECOL ONCOL, V97, P178, DOI 10.1016/j.ygyno.2004.12.015 | - |
hcfmusp.relation.reference | Chen YF, 2001, INT J CANCER, V91, P41, DOI 10.1002/1097-0215(20010101)91:1<41::AID-IJC1009>3.0.CO;2-2 | - |
hcfmusp.relation.reference | Claffey KP, 1996, CANCER RES, V56, P172 | - |
hcfmusp.relation.reference | Demidenko ZN, 2008, ONCOGENE, V27, P4402, DOI 10.1038/onc.2008.82 | - |
hcfmusp.relation.reference | Dias MLN, 2007, CANCER CHEMOTH PHARM, V59, P105, DOI 10.1007/s00280-006-0252-3 | - |
hcfmusp.relation.reference | Geran RI, 1972, PROTOCOLS SCREENING, P47 | - |
hcfmusp.relation.reference | Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487 | - |
hcfmusp.relation.reference | GINSBERG H, 1982, ANN INTERN MED, V96, P311 | - |
hcfmusp.relation.reference | Hande KR, 2006, UPDATE CANC THER, V1, P3, DOI 10.1016/j.uct.2006.04.001 | - |
hcfmusp.relation.reference | HENRIKSSON P, 1989, LANCET, V2, P1178 | - |
hcfmusp.relation.reference | Hirata RDC, 1999, BBA-MOL CELL BIOL L, V1437, P53, DOI 10.1016/S1388-1981(98)00004-3 | - |
hcfmusp.relation.reference | HO YK, 1978, BLOOD, V52, P1099 | - |
hcfmusp.relation.reference | Hungria VTM, 2004, CANCER CHEMOTH PHARM, V53, P51, DOI 10.1007/s00280-003-0692-y | - |
hcfmusp.relation.reference | Lin HL, 1998, ANTICANCER RES, V18, P3443 | - |
hcfmusp.relation.reference | Liu DH, 2010, CRIT REV THER DRUG, V27, P371 | - |
hcfmusp.relation.reference | Lo Prete AC, 2006, J PHARM PHARMACOL, V58, P801, DOI 10.1211/jpp.58.6.0010 | - |
hcfmusp.relation.reference | Lundberg BB, 2003, J CONTROL RELEASE, V86, P93, DOI 10.1016/S0168-3659(02)00323-1 | - |
hcfmusp.relation.reference | Maranhao RC, 2002, CANCER CHEMOTH PHARM, V49, P487, DOI 10.1007/s00280-002-0437-3 | - |
hcfmusp.relation.reference | MARANHAO RC, 1992, BRAZ J MED BIOL RES, V25, P1003 | - |
hcfmusp.relation.reference | MARANHAO RC, 1993, LIPIDS, V28, P691, DOI 10.1007/BF02535988 | - |
hcfmusp.relation.reference | MARANHAO RC, 1994, CANCER RES, V54, P4660 | - |
hcfmusp.relation.reference | NAKAGAWA T, 1995, J CLIN ENDOCR METAB, V80, P92, DOI 10.1210/jc.80.1.92 | - |
hcfmusp.relation.reference | Ophir R, 1999, J IMMUNOTHER, V22, P103, DOI 10.1097/00002371-199903000-00002 | - |
hcfmusp.relation.reference | Perez EA, 2009, MOL CANCER THER, V8, P2086, DOI 10.1158/1535-7163.MCT-09-0366 | - |
hcfmusp.relation.reference | Pinheiro KV, 2006, CANCER CHEMOTH PHARM, V57, P624, DOI 10.1007/s00280-005-0090-8 | - |
hcfmusp.relation.reference | Pires L, 2009, CANCER CHEMOTH PHARM, V63, P281, DOI 10.1007/s00280-008-0738-2 | - |
hcfmusp.relation.reference | Pires LA, 2012, BRAZ J MED BIOL RES, V45, P557, DOI 10.1590/S0100-879X2012007500068 | - |
hcfmusp.relation.reference | Rodrigues DG, 2005, CANCER CHEMOTH PHARM, V55, P565, DOI 10.1007/s00280-004-0930-y | - |
hcfmusp.relation.reference | Schonn I, 2010, APOPTOSIS, V15, P162, DOI 10.1007/s10495-009-0440-9 | - |
hcfmusp.relation.reference | Stranzl A, 1997, BREAST CANCER RES TR, V42, P195, DOI 10.1023/A:1005754026205 | - |
hcfmusp.relation.reference | Teixeira RS, 2004, J PHARM PHARMACOL, V56, P909, DOI 10.1211/0022357023826 | - |
hcfmusp.relation.reference | Teixeira RS, 2008, J PHARM PHARMACOL, V60, P1287, DOI 10.1211/jpp/60.10.0004 | - |
hcfmusp.relation.reference | Torres K, 1998, CANCER RES, V58, P3620 | - |
hcfmusp.relation.reference | UEYAMA Y, 1990, LANCET, V336, P707, DOI 10.1016/0140-6736(90)92204-U | - |
hcfmusp.relation.reference | Valduga CJ, 2003, J PHARM PHARMACOL, V55, P1615, DOI 10.1211/0022357022232 | - |
hcfmusp.relation.reference | van Kempen LCLT, 2008, INT J CANCER, V122, P1019, DOI 10.1002/ijc.23147 | - |
hcfmusp.relation.reference | Versluis AJ, 1996, BRIT J CANCER, V74, P525, DOI 10.1038/bjc.1996.396 | - |
hcfmusp.relation.reference | VITOLS S, 1992, CANCER RES, V52, P6244 | - |
hcfmusp.relation.reference | VITOLS S, 1990, P NATL ACAD SCI USA, V87, P2598, DOI 10.1073/pnas.87.7.2598 | - |
hcfmusp.relation.reference | Wei FX, 2010, CELL SIGNAL, V22, P1783, DOI 10.1016/j.cellsig.2010.07.007 | - |
hcfmusp.relation.reference | Yue QX, 2010, PLANTA MED, V76, P1037, DOI 10.1055/s-0030-1250073 | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | CNPq | - |
hcfmusp.remissive.sponsorship | FAPESP | - |
hcfmusp.lim.ref | 2012 | - |
hcfmusp.citation.scopus | 33 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - LIM/31 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_MARANHAO_Drug_targeting_in_combined_cancer_chemotherapy_tumor_growth_2012.PDF Restricted Access | publishedVersion (English) | 593.24 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.